|
The Shift to Net Price: It’s been a long time coming and at times very slow moving, but the market is shifting away from heavily relying on rebates to net pricing. The dynamics around MFN, IRA, DTC, PBM legislation/policy, and recent news from payers, such as Cigna, are causing an inevitable shift away from relying on rebates when pricing products. In our view, PBM leverage will continue to shrink in the future, and payers/employers are focused on moving to transparent net pricing tied to outcomes. The negotiating table is pivoting from “rebate-max” to value-first, evidence-backed contracting across all markets—from crowded primary-care classes to ultra-rare one-time therapies.
What does this likely mean?
· List↔Net compression: Launch and renewals will be moving from “high list/large rebate” to “right net from day one.”
· Direct payer/employer deals: Expect more customized contracts, outcomes terms, and employer coalitions.
· Formulary criteria evolve: Less weight on rebate size, more on clinical differentiation, real-world performance, and total-cost impact.
· PBM role pivots: From gatekeeper to admin/analytics; execution quality and data pipes matter as much as price.
Manufacturers need to further strengthen and prepare the evidence & value story
· Upgrade real world evidence (RWE), build payer-grade dossiers (claims/EHR/registry), pre-specify endpoints that tie to medical-cost offsets (acute events avoided, persistence, time to control).
· Define value transparently: Publish budget-impact models and value frameworks; arm account teams with calculator-ready tools.
· Offer outcomes menus, keep admin light: Adherence guarantees, hospitalization triggers, biomarker milestones, “warranty” constructs—objective, auditable, simple.
Contracting & negotiation playbook in a net price era
· Bring “net price cards” by segment: National plans, Blues, Medicaid MCOs, jumbo employers—each with volume, access, and outcomes tiers. Every segment may have a different strategy regarding location, member/employer profile, etc.
· Align patient cost share to net: Support fixed copays or coinsurance on net to deliver OOP relief and adherence gains.
· Operational readiness wins: Clear claims rules, data-sharing, and shared dashboards with periodic true-ups.
Segment-specific guidance (addressing all markets)
1) Crowded classes with active competition (e.g., cardiometabolic, immunology, respiratory)
· Expectation: Net price pressure will be strong; formularies will reward verified real-world performance and ease-of-use.
· Win themes: Transparent nets, speed-to-control, simplified step edits/PA, adherence services, patient affordability programs tied to net.
· Tactics: Value-based addenda (e.g., A1c/FEV1/flare reductions), class-comparative RWE, co-created care pathways.
2) Specialty classes with partial competition (e.g., MS, IBD, oncology sub-lines)
· Expectation: Moderate net pressure; access hinges on biomarker fit, persistence, site-of-care efficiency.
· Win themes: Head-to-head or anchored indirect comparisons, time-on-therapy, infusion/administration productivity, site-of-care optimization.
· Tactics: Outcomes triggers on acute utilization, portfolio bundles, center-of-excellence access SLAs.
3) Biosimilars (and brands facing them)
· Expectation: Multi-winner formularies; reliability and interchangeability support are decisive.
· Win themes: Supply assurance, switching support, interoperability with EMR/e-prescribing, patient services.
· Tactics: Tiered transparent nets, portfolio bundles, operational guarantees (fill rates, backorder clauses).
4) Limited-competition / unique therapies (including rare & ultra-rare and one-time treatments)
· Expectation: Most favorable price-setting leverage—may be tempered by payer uncertainty and budget impact.
· Win themes: Gold-standard evidence (natural history, external controls), simple outcome warranties, annuity/installment options, reinsurance linkages.
· Tactics: Coverage-with-evidence-development, center-of-excellence pathways, diagnostic pull-through (testing/navigation), equity solutions for small plans (risk pools/aggregators).
Organization & capability shifts need to be in motion
· RWE factory: In-house/partner engine to ingest claims/EHR/registry data and publish quarterly payer-grade briefs—with rare-disease annexes.
· Value engineering pre-NDA: Price-to-value models by segment (employer, Medicaid, IDN), scenario ranges for net-first launches.
· Contract ops 2.0: Standardized, low-admin outcomes clauses; rapid dispute resolution; data-sharing playbooks.
· Field model upgrade: Add payer account scientists and pathway experts who can co-design budget impact and outcomes pilots.
Metrics that will matter in renewals
· Total cost of care per treated member
· Time to clinical control & persistence
· Avoided ED/IP events and site-of-care efficiency
· Verified adherence uplift vs. baseline
· Patient OOP reduction & time-to-access
· For rare/ultra-rare: milestone attainment, registry completeness, center-of-excellence adherence
The takeaway: In a net-price, outcomes-attached world, differentiation lives in evidence, simplicity, and sometimes shared risk. In competitive classes, win with transparent nets plus measurable, low-friction outcomes value. In rare/ultra-rare, leverage is very real in the early stages but sustaining it is the difficult part. Manufacturers need to prepare to gather rigorous evidence, budget-smoothing mechanics, and COE-enabled access. Manufacturers that prove real-world value and make contracting effortless will secure access at sustainable nets—while others keep negotiating yesterday’s playbook.
| 
